Search Results for "fluticasone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fluticasone. Results 11 to 12 of 12 total matches.
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
are recommended
(off-label) for treatment of EoE. Options have included
fluticasone from a metered-dose inhaler ...
Eohilia (Takeda), an oral suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment of eosinophilic esophagitis
(EoE) in patients ≥11 years old. It is the first oral
drug to be approved in the US for this indication. The
subcutaneously injected interleukin (IL)-4 receptor
antagonist dupilumab (Dupixent) is approved
for treatment of EoE in patients ≥1 year old who
weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5 doi:10.58347/tml.2024.1704c | Show Introduction Hide Introduction
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
but no formulations are currently approved
by the FDA for this indication. Fluticasone from a
metered-dose inhaler ...
The FDA has approved the subcutaneously
injected interleukin (IL)-4 receptor alpha antagonist
dupilumab (Dupixent – Sanofi/Regeneron)
for treatment of eosinophilic esophagitis (EoE)
in patients ≥12 years old who weigh ≥40 kg and
treatment of prurigo nodularis in adults. Dupilumab
is the first drug to be approved in the US for each
of these indications. It is also FDA-approved for
treatment of atopic dermatitis, asthma, and chronic
rhinosinusitis with nasal polyposis.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):18-20 doi:10.58347/tml.2023.1669b | Show Introduction Hide Introduction